Skip to Content

What Is the Best Treatment for Elderly Patients With AML?

AML in the groupe of patients older than 60/65 years has a poor long-term survival. So what is the best treatment for this group of patients?. In this Medtalk, Bjørn Tore Gertsen addresses new treatment possibilities and he look forward to the approval for venetoclax. At least he present the Nordic LD-VenEx clinical trial for Acute Myeloid Leukaemia performed by Waleed Ghanima.

Bjørn Tore Gjertsen

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top